Precigen (PGEN) Non-Current Debt (2013 - 2026)

Precigen (PGEN) posted quarterly Non-Current Debt of $93.5 million for Q1 2026, little changed quarter-over-quarter from $93.2 million in Q4 2025.

Precigen (PGEN) Non-Current Debt (2013 - 2026) Analysis & Trends

Precigen (PGEN) has reported Non-Current Debt for 12 consecutive years, with $93.5 million the latest figure, recorded in Q1 2026.

In Q1 2026, Non-Current Debt changed N/A year-over-year to $93.5 million; the TTM figure through Mar 2026 stood at $93.5 million (changed N/A YoY), while the FY2025 annual figure was $93.2 million, changed N/A from the prior year.
Non-Current Debt steadied at $93.5 million in Q1 2026 per PGEN's latest filing, from $93.2 million in the prior quarter.
Across five years, Non-Current Debt topped out at $201.1 million in Q1 2022 and bottomed at $43.2 million in Q4 2022.
Historically, Non-Current Debt has averaged $120.4 million across 3 years, with a median of $93.3 million in 2025.
On a YoY basis, Non-Current Debt climbed as much as 15.24% in 2022 and fell as far as 75.97% in 2022.
Precigen's Non-Current Debt stood at $43.2 million in 2022, then jumped by 115.59% to $93.2 million in 2025, then increased by 0.37% to $93.5 million in 2026.
Business Quant data shows PGEN's Non-Current Debt at $93.5 million in Q1 2026, $93.2 million in Q4 2025, and $92.9 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	882.16 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	8.96 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Precigen	2.18 Bn	2.18 Bn	52.17 Mn	93.88 Mn

Download Data